Defining and targeting wild-type BRCA high-grade serous ovarian cancer : DNA repair and cell cycle checkpoints
Introduction: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. Areas covered: In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. Expert opinion: Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 28(2019), 9 vom: 11. Sept., Seite 771-785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ivy, S Percy [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.10.2019 Date Revised 24.10.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2019.1657403 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300593945 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300593945 | ||
| 003 | DE-627 | ||
| 005 | 20231225102840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2019.1657403 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300593945 | ||
| 035 | |a (NLM)31449760 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ivy, S Percy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Defining and targeting wild-type BRCA high-grade serous ovarian cancer |b DNA repair and cell cycle checkpoints |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.10.2019 | ||
| 500 | |a Date Revised 24.10.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. Areas covered: In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. Expert opinion: Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ATM | |
| 650 | 4 | |a ATR | |
| 650 | 4 | |a BRCA wild type | |
| 650 | 4 | |a BRCAwt | |
| 650 | 4 | |a CHK1 | |
| 650 | 4 | |a CHK2 | |
| 650 | 4 | |a DNA damage repair | |
| 650 | 4 | |a DNA repair deficiencies | |
| 650 | 4 | |a DNA-PKcs | |
| 650 | 4 | |a Homologous recombination | |
| 650 | 4 | |a PARP | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cell cycle | |
| 650 | 4 | |a high grade serous ovarian cancer | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 protein, human |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 protein, human |2 NLM | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 700 | 1 | |a Kunos, Charles A |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaldez, Fernanda I |e verfasserin |4 aut | |
| 700 | 1 | |a Kohn, Elise C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 28(2019), 9 vom: 11. Sept., Seite 771-785 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2019 |g number:9 |g day:11 |g month:09 |g pages:771-785 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2019.1657403 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2019 |e 9 |b 11 |c 09 |h 771-785 | ||